ArticleCancer epidemiology2020
Risk of subsequent malignant neoplasms after an index potentially-human papillomavirus (HPV)-associated cancers.
Article in Cancer epidemiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Low Rates of Dual-Site and Concordant Oral-Cervical Human Papillomavirus Infections and Cancers: A Systematic Review.Frontiers in oncology · 2022Pooled it
- Awareness of the link between HPV and cancer according to cancer type and gender in the US from 2014-2020.Human vaccines & immunotherapeutics · 2026Article
- Higher-order multiple primary cancers and persistent cross-site risk across human papillomavirus-related anatomical sites in the United States: a population-based Surveillance, Epidemiology, and End Results study.Preventive medicine reports · 2026Article
- A study on the temporal patterns, anatomical distribution, and influencing factors of radiation therapy-associated second primary cancers in gynecological malignancies.Frontiers in oncology · 2026Article
- Awareness of HPV, HPV vaccine and HPV-associated cancers among Arab Americans.Scientific reports · 2025Article
- Emerging Therapeutic Strategies for Lung Cancer: The Role of Immunotherapy and HPV-Targeted Cancer Vaccines.Vaccines · 2025Review
- Molecular interaction of human papilloma virus (HPV) with microRANs: insights into the development of cervical cancer and treatment approaches.Infectious agents and cancer · 2025Review
- Treatment of Condyloma Acuminata with Tirbanibulin 1% Ointment in People Living with HIV: A Case Series with Literature Review.Infectious disease reports · 2025Review
- Article
- Anal Cancer and Anal Intraepithelial Neoplasia Risk among Patients Treated for HPV-Related Gynecological Diseases-A Systematic Review.Journal of clinical medicine · 2023Review
- College Students' Awareness of the Link Between Human Papillomavirus (HPV) and HPV-Associated Cancers.Journal of cancer education : the official journal of the American Association for Cancer Education · 2023Article
- Rural-Urban Disparities in HPV Vaccination Coverage Among Adolescents in the Central Part of the State of Illinois, USA.Journal of community health · 2023Article
- Article
- Association between Sexual Activity and Human Papillomavirus (HPV) Vaccine Initiation and Completion among College Students.Vaccines · 2022Article
- Medical students' knowledge of HPV, HPV vaccine, and HPV-associated head and neck cancer.Human vaccines & immunotherapeutics · 2022Article
- Article
- Human Papillomavirus-Associated Sexual Risks Among High School Students in the U.S.: Does Sexual Orientation Play a Role?Archives of sexual behavior · 2021Article
- Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis.Cancer medicine · 2021Article
- Geographic Variation in Human Papillomavirus Vaccination Initiation and Completion Among Young Adults in the U.S.American journal of preventive medicine · 2021Article
- Disparities in human papillomavirus (HPV) vaccine initiation and completion based on sexual orientation among women in the United States.Human vaccines & immunotherapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundSince the number of cancer survivors is increasing, it is imperative that we better understand the long-term consequences of these survivors. We assessed the risk of developing a second primary malignant neoplasm (SPMN) after an index potentially-HPV-associated cancers (P-HPV-AC).
methodsWe constructed a population-based cohort of patients with P-HPV-AC using Surveillance, Epidemiology, and End Results registry data (2000-2015). We limited patients to those with invasive P-HPV-AC [cervical, vagina, vulva, penile, anal, and oropharynx] based on the International Classification of Diseases for Oncology, 3rd edition. Excess SPMN risks were calculated based on standardized incidence ratios (SIRs) and excess absolute risks (EARs) per 10,000 person-years at risk (PYR).
resultsA total of 105,644 patients with an index P-HPV-AC were identified, and 7.8 % developed a SPMN. In all P-HPV-AC patients, the overall SIR was 1.73 (95 % CI: 1.69-1.77) and EAR of 70.72 per 10,000 PYR. All index P-HPV-AC sites showed statistically significant increases in the risk of SPMN, except for anal cancer among men, compared with the general population. The greatest increase in risk of SPMN was observed among patients diagnosed with an index P-HPV-oropharyngeal cancer (SIR = 1.83; 95 % CI, 1.70-1.82 and SIR = 2.29; 95 % CI, 2.12-2.47 for men and women, respectively). Men developed SPMN mostly in aero-digestive tract whiles women developed SPMN both in aero-digestive tract and other HPV-associated cancer sites.
conclusionsP-HPV-AC survivors experienced excess risk of SPMN. These findings have the potential to affect future surveillance practices and improve preventive healthcare for survivors of P-HPV-ACs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.